Cargando…

HIF1A predicts the efficacy of anti-PD-1 therapy in advanced clear cell renal cell carcinoma

Immunotherapy for cancer has become a revolutionary treatment, with the progress of immunological research on cancer. Cancer patients have also become more diversified in drug selection. Individualized medical care of patients is more important in the era of precision medicine. For advanced clear ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Tuanjie, Wang, Tao, Zhang, Jian, Chen, Siteng, Wang, Xiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2022
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530654/ https://www.ncbi.nlm.nih.gov/pubmed/36191462 http://dx.doi.org/10.1016/j.tranon.2022.101554

Ejemplares similares

Cuproptosis-Related Genes Are Associated with Cell Cycle and Serve as the Prognostic Signature for Clear Cell Renal Cell Carcinoma
por: Guo, Tuanjie, et al.
Publicado: (2022)

Screening and identification of prognostic genes associated with eosinophilic features of clear cell renal cell carcinoma()
por: Guo, Tuanjie, et al.
Publicado: (2023)

Lactic Acid Metabolism and Transporter Related Three Genes Predict the Prognosis of Patients with Clear Cell Renal Cell Carcinoma
por: Guo, Tuanjie, et al.
Publicado: (2022)

Machine learning-based prognosis signature for survival prediction of patients with clear cell renal cell carcinoma
por: Chen, Siteng, et al.
Publicado: (2022)

A novel ferroptosis-related gene signature associated with cell cycle for prognosis prediction in patients with clear cell renal cell carcinoma
por: Chen, Siteng, et al.
Publicado: (2022)

Robust Prediction of Prognosis and Immunotherapeutic Response for Clear Cell Renal Cell Carcinoma Through Deep Learning Algorithm
por: Chen, Siteng, et al.
Publicado: (2022)

Artificial intelligence-based non-invasive tumor segmentation, grade stratification and prognosis prediction for clear-cell renal-cell carcinoma
por: Chen, Siteng, et al.
Publicado: (2023)

The therapeutic potential of HIF-2 antagonism in renal cell carcinoma
por: Cuvillier, Olivier
Publicado: (2017)

Towards Personalized Sampling in Clear Cell Renal Cell Carcinomas
por: Manini, Claudia, et al.
Publicado: (2022)

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
por: Au, Lewis, et al.
Publicado: (2021)

HIF-1α Inhibition Improves Anti-Tumor Immunity and Promotes the Efficacy of Stereotactic Ablative Radiotherapy (SABR)
por: Song, Chang W., et al.
Publicado: (2022)

A Novel m(6)A Gene Signature Associated With Regulatory Immune Function for Prognosis Prediction in Clear-Cell Renal Cell Carcinoma
por: Chen, Siteng, et al.
Publicado: (2021)

Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer
por: Chen, Siteng, et al.
Publicado: (2019)

Identification of an endogenous retroviral signature to predict anti-PD1 response in advanced clear cell renal cell carcinoma: an integrated analysis of three clinical trials
por: Zhou, Jian-Guo, et al.
Publicado: (2022)

Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell Carcinoma
por: Aili, Abudureyimujiang, et al.
Publicado: (2021)

The study on copy number alteration of clear cell renal cancer in Chinese population
por: Zhang, Ning, et al.
Publicado: (2020)

The up‐regulation of NDRG1 by HIF counteracts the cancer‐promoting effect of HIF in VHL‐deficient clear cell renal cell carcinoma
por: Zhang, Zheng‐Yan, et al.
Publicado: (2020)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

In tumor cells, thyroid hormone analogues non-immunologically regulate PD-L1 and PD-1 accumulation that is anti-apoptotic
por: Lin, Hung-Yun, et al.
Publicado: (2018)

Histone demethylase KDM4B contributes to advanced clear cell renal carcinoma and association with copy number variations and cell cycle progression
por: Tang, Heting, et al.
Publicado: (2023)

Fatty acids metabolism affects the therapeutic effect of anti-PD-1/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma
por: Lin, Hansen, et al.
Publicado: (2023)

Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
por: Montemagno, Christopher, et al.
Publicado: (2020)

Effects of HIF-1α and HIF2α on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts
por: Biswas, Swethajit, et al.
Publicado: (2010)

Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer
por: Szendrői, Attila, et al.
Publicado: (2016)

HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice
por: Hoefflin, Rouven, et al.
Publicado: (2020)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
por: Spirina, Liudmila, et al.
Publicado: (2021)

PD‐1/PD‐L1 inhibitors‐based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies
por: Ding, Lei, et al.
Publicado: (2021)

A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy
por: Lin, Jingwei, et al.
Publicado: (2023)

Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response
por: Rupp, Tristan, et al.
Publicado: (2022)

HIF1α is not a target of 14q deletion in clear cell renal cancer
por: Shenoy, Niraj
Publicado: (2020)

Regulation of HIF-1α stability by lysine methylation
por: Baek, Sung Hee, et al.
Publicado: (2016)

Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma
por: Deutsch, Julie Stein, et al.
Publicado: (2023)

Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma
por: GE, WENFEI, et al.
Publicado: (2023)

Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma
por: Dufies, Maeva, et al.
Publicado: (2021)

Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)
por: Bialek, Joanna, et al.
Publicado: (2022)

Concordance of PD‐1 and PD‐L1 (B7‐H1) in paired primary and metastatic clear cell renal cell carcinoma
por: Eckel‐Passow, Jeanette E., et al.
Publicado: (2019)

The RNA-binding protein QKI suppresses tumorigenesis of clear cell renal cell carcinoma by regulating the expression of HIF-1α
por: Shi, Fei, et al.
Publicado: (2020)

Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma
por: Larrinaga, Gorka, et al.
Publicado: (2021)

Autocrine stimulation of clear-cell renal carcinoma cell migration in hypoxia via HIF-independent suppression of thrombospondin-1
por: Bienes-Martínez, Raquel, et al.
Publicado: (2012)

HIF2α promotes tumour growth in clear cell renal cell carcinoma by increasing the expression of NUDT1 to reduce oxidative stress
por: Shi, Jian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rrqu5e3shkk01ov40i9ujp0t57